Sorted By Test Name - Mayo Medical Laboratories

BADX
89006
Interpretation: Detection of IgE antibodies in serum (Class 1 or greater) indicates an increased
likelihood of allergic disease as opposed to other etiologies and defines the allergens that may be
responsible for eliciting signs and symptoms. The level of IgE antibodies in serum varies directly with the
concentration of IgE antibodies expressed as a class score or kU/L.
Reference Values:
Class IgE kU/L Interpretation
0 Negative
1 0.35-0.69 Equivocal
2 0.70-3.49 Positive
3 3.50-17.4 Positive
4 17.5-49.9 Strongly positive
5 50.0-99.9 Strongly positive
6 > or =100 Strongly positive Reference values
apply to all ages.
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by
Laboratory Methods. 21st edition. Edited by RA McPherson, MR Pincus. New York, WB Saunders
Company, 2007, Chapter 53, Part VI, pp 961-971
BCR/ABL, mRNA Detection, Reverse Transcription-PCR
(RT-PCR), Qualitative, Diagnostic Assay
Clinical Information: mRNA transcribed from BCR/ABL (fusion of the breakpoint cluster region
gene [BCR] at chromosome 22q11 to the Abelson gene [ABL] at chromosome 9q23) is detected in all
chronic myelogenous leukemia (CML) patients and a subset of both acute lymphoblastic leukemia (ALL)
and acute myeloid leukemia (AML) patients. Although breakpoints in the BCR and ABL genes may occur
in a variety of locations, splicing of the primary RNA transcripts result in only 8 fusion site variants
(e1/a2, e6/a2, e13/a2, e14/as, e19/a2, e1/a3, e13/a3, e14/a3) which incorporate the entire sequence of the
exons on both sides of the fusion site. Although not reported in the literature, additional fusion variants
(e20/a2, e6/a3, e12/a3, e19/a3, e20/a3) could theoretically result in disease-promoting bcr/abl proteins.
Very rare, single-case reports of patients with fusions sites within the exons of BCR or ABL are also
present in the literature. In CML, >95% of patients have either an e13/a2 or e14/a2 fusion, both of which
produce a 210-kDa protein (p210). More than 50% of patients with BCR/ABL-positive ALL have the
e1/a2 fusion, which produces a 190-kDa protein (p190), and the majority of the remaining patients have
either the e13/a2 or e14/a2 variants. Other fusions are very rare in any of the neoplasms known to harbor
BCR/ABL. When looking for the presence of mRNA from BCR/ABL (bcr/abl) at the time of diagnosis, it
is important to use an assay that detects as many of the fusions as possible and identifies which fusion is
present. This avoids false-negative results at diagnosis and assures the test subsequently selected for
monitoring during therapy will detect the appropriate fusion product in each patient. This assay is
designed to detect essentially all reported and theoretical BCR/ABL mRNA fusion variants.
Useful For: Aids in the diagnostic workup for patients with bcr/abl-positive neoplasms, predominantly
chronic myeloid leukemia and acute lymphocytic leukemia When positive, the test identifies which
mRNA fusion variant is present to guide selection of an appropriate monitoring assay. If a quantitative
monitoring assay is not available for a rare fusion variant, this assay may be of some value for monitoring,
as it is quite sensitive and can provide a positive or negative result.
Interpretation: An interpretive report will be provided.
Reference Values:
A qualitative result is provided that indicates the presence or absence of BCR/ABL mRNA. When
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 230